In breast tumors, NR0B2 expression is negatively correlated with FOXP3, a marker for Tregs, suggesting that NR0B2 may reduce immunosuppression in the tumor microenvironment [4,5]. This evidence concerns the gene NR0B2 and breast neoplasm.